UpToDate—the popular clinical research and information database used by thousands of hospitals around the globe—has officially tacked on an AI solution. As one family physician put it, who currently ...

Failures by the standalone LLMs often stemmed from hallucinations, outdated knowledge, or misinterpretation of clinical rules. For example, the LLM on its own provided obsolete age eligibility ...

Annotating regions of interest in medical images, a process known as segmentation, is often one of the first steps clinical researchers take when running a new study involving biomedical images.

Molecular profiling has transformed cancer care, but 30% of high-risk pediatric cancers do not have actionable therapeutic targets, limiting personalized treatment options and negatively affecting ...

Tom Cowen, head, healthcare, life sciences, Conga, shares how leading pharmaceutical companies are using Contract Lifecycle Management to streamline global studies, reduce onboarding times, and ...

Do you worry your clinical laboratory is falling behind in the race to adopt artificial intelligence (AI) technologies? Every day, labs are inundated with media and marketing messages about artificial ...

The larval zebrafish model holds a significant promise to improve the efficiency of evaluating personalized treatment options for the greatest number of pediatric patients with cancer, providing ...

Recognition by The Healthcare Technology Report underscores TriNetX's innovation in real-world data, artificial intelligence, and clinical research transformati ...

Background: Determining optimal timing for intensifying the frequency of physician encounters for type 2 diabetes mellitus (T2DM) requires trade-offs between timely care and clinician burden. We aimed ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab ...

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead investigational drug PV-10 in an orthotopic bladder cancer ...